Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: June 29, 2023 (Event Date: July 12, 2023)
Context: The Company, incorporated in Delaware with principal offices in Australia, reported the entry into two material definitive agreements to secure financing for general working capital and debt repayment.
Key Financial Metrics and Agreements
This filing details two distinct financing instruments rather than standard periodic financial results (revenue, profit, or cash flow statements are not included in this 8-K).
| Instrument | Principal Amount | Interest Rate | Maturity | Key Terms |
|---|---|---|---|---|
| June Note (Convertible Promissory Note) |
$65,000 USD | 8% per annum (22% on default) |
June 29, 2024 | Convertible to Common Stock at 65% of market price after 180 days. Prepayment penalties range from 110% to 129% depending on timing. Requires 500% reserve of conversion shares. |
| July Loan (Letter Agreement) |
AU$230,000 | 10% per annum | July 5, 2026 | Used to repay ~$143,000 of defaulted debt. Includes warrant for 15,000,000 shares at $0.01/share. Interest paid monthly in arrears. |
Material Changes and Unusual Items
- Debt Restructuring: The July Loan proceeds were specifically utilized to repay an outstanding balance of approximately $143,000 on a convertible promissory note that was currently in default.
- Equity Dilution Risk: The June Note allows conversion at a significant discount (65% of market price), and the July Loan includes a warrant for 15 million shares at a nominal exercise price ($0.01), creating substantial potential dilution.
- Default Penalties: The June Note carries severe default consequences, including immediate acceleration of the debt at 150% of the outstanding principal plus accrued interest.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use the net proceeds from the June Note ($65,000) for general working capital purposes. The July Loan proceeds were used for debt repayment.
Risks and Contingencies:
- Liquidity Constraints: The Company has limited prepayment rights on the June Note for the first 180 days, and prepayment thereafter incurs significant premiums (up to 129%).
- Asset Disposition Restrictions: The Company cannot sell or dispose of substantially all assets without the June Investor's consent while the note is outstanding.
- Reporting Obligations: Failure to maintain OTC market listing or comply with Exchange Act reporting requirements constitutes an event of default.
Investor Verification Checklist
- Verify the current status of the previously defaulted convertible promissory note (approx. $143,000) to confirm full repayment.
- Review the Company's current cash position to assess ability to service the new 8% and 10% interest obligations.
- Calculate the potential dilution impact of the 15,000,000 warrant shares and the June Note conversion at 65% of market price.
- Confirm the Company's compliance with OTC listing requirements to avoid triggering the 150% default penalty on the June Note.